A Focus on Alpha-1 Blockade as a Novel Pharmacological Treatment for AUD
Brown University
Summary
The goal of this research is to replicate findings previously conducted in a pilot trial and to understand, mechanistically, the role of stress in the development of AUD pharmacotherapies that target noradrenergic blockade.
Description
16 week, between-subject, double-blind, randomized clinical trial (RCT) with doxazosin (16 mg, or maximum tolerated dose, MTD) compared to placebo in 184 treatment seeking individuals with AUD
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Male or female, 18 years of age * Meet the DSM-5 criteria for AUD * Desire to reduce or quit alcohol drinking * Breath alcohol (BrAC) = 0.00 at each visit * In good health as confirmed by medical history, physical examination and lab tests * Willing to adhere to the study procedures * Understand informed consent and questionnaires in English at an 8th grade level Exclusion Criteria: * Women who are breastfeeding or /positive urine test for pregnancy * CrCl\<60mL/min * Suicide attempt in the last three months * Current diagnosis of other substance disorder other than ni…
Interventions
- DrugDoxazosin
16 mg or maximum tolerated dose (MTD)
- DrugPlacebo
Matching placebo
Location
- Brown UniversityProvidence, Rhode Island